Form 4: Guardant Health CIO Granted 13,632 RSUs

Guardant Health's Chief Information Officer, Kumud Kalia, received a grant of 13,632 Restricted Stock Units with a three-year vesting schedule.

Summary

• Kumud Kalia, Chief Information Officer of Guardant Health, Inc. (GH), was granted 13,632 Restricted Stock Units (RSUs).
• The RSU award was granted on March 11, 2026.
• The vesting schedule for the RSUs is over a three-year period.
• 33% of the shares subject to the award will vest on April 1, 2027.
• The remaining 67% of the shares will vest in equal quarterly installments over the subsequent two-year period following April 1, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. While not directly impacting immediate financial performance, it signifies continued executive alignment and retention, which is generally favorable for corporate stability.

Positives

• The RSU grant aligns the Chief Information Officer's interests with those of shareholders, promoting long-term commitment and performance.
• This form of compensation is a standard practice for executive retention and motivation in publicly traded companies.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive compensation event.

Industry Context

StockSavvy.ai notes that RSU grants are a common and effective mechanism for executive compensation across the biotechnology and healthcare technology sectors. This practice helps to retain key talent and align management incentives with long-term shareholder value creation, a standard in competitive industries like diagnostics and precision oncology where Guardant Health operates.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a Chief Information Officer is a standard compensation practice, comparable to similar grants observed at peer companies in the diagnostic and healthcare technology space such as Illumina, Exact Sciences, and Foundation Medicine.
• The three-year vesting schedule with an initial cliff and subsequent quarterly installments is a common structure designed to encourage long-term executive retention and performance, aligning with industry benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with shareholder value creation over the long term, potentially leading to better performance. However, it also represents future dilution as shares vest.
• Employees: This grant reinforces the company's commitment to executive compensation and retention, which can positively influence overall employee morale and perception of career opportunities.

Next Steps

• The vesting of 33% of the RSUs on April 1, 2027.
• Subsequent quarterly vesting of the remaining 67% of RSUs over the two-year period following April 1, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for Guardant Health. While positive for executive alignment, it is not a catalyst for a change in recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Guardant Health, GH, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Kumud Kalia